Hope Tribune

Delveinsight Business Research LLP

The Geographic Atrophy market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Geographic Atrophy: An Overview

Geographic Atrophy (GA) is an advanced form of age-related macular degeneration (AMD). Macular degeneration also called age-related macular degeneration (AMD or ARMD) is a medical condition that may result in blurred or no vision in the center of the visual field. There are two basic types of macular degeneration: “dry” and “wet”. According to the “American Macular Degeneration Foundation,” approximately 85–90% of the cases of macular degeneration are the “dry” (atrophic) type.

Currently, there are no approved treatments present for Geographic Atrophy. The Age-Related Eye Disease Study (AREDS) study suggested that supplementing the diet of patients with vitamin C, vitamin E, beta-carotene, and zinc could significantly reduce the risk of progressing to advanced AMD, and sometimes low visual aids and counseling is also helpful. Several therapies which reached an advanced stage of development are already failed, however, currently, several therapies are in the pipeline to prevent the progression of GA.

Geographic Atrophy Market Key Facts

• In the year 2020, the total prevalent case of Geographic Atrophy was 2,969,900+ cases in the 7MM. These cases are expected to grow with a significant CAGR in the study period 2018–2030.

• In the 7MM, the total diagnosed cases of Geographic Atrophy were 2,742,600+ cases in 2020. 

• In the 7MM, the total treated cases of Geographic Atrophy were 1,267,300+ cases in 2020.

• Globally, more than 5 million people are affected by GA. Also, as per the published study by the GER group, the global prevalence of GA is 0.66% in all ages, but it occurs in 0.34% for 65–74 years old, 1.3% for 75–84, and 4.4% over 85 years old.

Geographic Atrophy Market

As per DelveInsight, the Geographic Atrophy Market is expected to grow significantly in the upcoming years owing to the expected launch and readily uptake of emerging therapies along with premium price agents like gene therapies, increasing prevalent patient pool, and a better understanding of pathophysiology, disease severity which might open the door for other companies as well.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Geographic Atrophy market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Geographic Atrophy market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Geographic Atrophy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Geographic Atrophy (GA) Epidemiology Segmentation –

• Total Prevalent Cases of Geographic Atrophy

• Total Diagnosed cases of Geographic Atrophy

• Treated cases of Geographic Atrophy

• Diagnosed cases of Geographic Atrophy by Age Distribution

• Total Geographic Atrophy Cases by Visual Impairment

Geographic Atrophy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Geographic Atrophy market or expected to get launched during the study period. The analysis covers Geographic Atrophy market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Geographic Atrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market

Geographic Atrophy Therapeutics Analysis

The Geographic Atrophy (GA) market dynamics is anticipated to change in the coming years owing to the launch of novel drugs and rising healthcare spending across the world.

Some of the key companies in the Geographic Atrophy (GA) Market include:

• Apellis Pharmaceuticals

• Iveric Bio

• Hemera Biosciences

• Gyroscope Therapeutics

• Stealth BioTherapeutics

• Roche (Genentech)

• CellCure Neurosciences

And many others.

Geographic Atrophy (GA) Therapies covered in the report include:

• Zimura (Avacincaptad Pegol)

• Pegcetacoplan

• HMR59/AAVCAGsCD59

• Risuteganib

• Elamipretide

• ALK-001

• Palucorcel/CNTO 2476

And many more. 

Get More Detailed Insights Into the Emerging Therapies & Key Companies –  https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Geographic Atrophy Competitive Intelligence Analysis

4. Geographic Atrophy Market Overview at a Glance

5. Geographic Atrophy Disease Background and Overview

6. Geographic Atrophy Patient Journey

7. Geographic Atrophy Epidemiology and Patient Population

8. Geographic Atrophy Treatment Algorithm, Current Treatment, and Medical Practices

9. Geographic Atrophy Unmet Needs

10. Key Endpoints of Geographic Atrophy Treatment

11. Geographic Atrophy Marketed Products

12. Geographic Atrophy Emerging Therapies

13. Geographic Atrophy Seven Major Market Analysis

14. Attribute Analysis

15. Geographic Atrophy Market Outlook (7 major markets)

16. Geographic Atrophy Access and Reimbursement Overview

17. KOL Views on the Geographic Atrophy Market.

18. Geographic Atrophy Market Drivers

19. Geographic Atrophy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/geographic-atrophy-ga-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Scleritis Market

“Scleritis Market” report provides a detailed overview of the disease and an in-depth understanding of historical and forecasted epidemiology as well as the Scleritis market size, share, trends, and forecast in the 7MM.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/